Tumor vaccines: Toward multidimensional anti-tumor therapies

References

• Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):41. doi:10.1186/s12943-021-01335-5.
   PubMed Web of Science ®Google Scholar
• Zamani P, Navashenaq JG, Teymouri M, Karimi M, Mashreghi M, Jaafari MR. Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy. Life Sci. 2020;252:117646. doi:10.1016/j.lfs.2020.117646.
   PubMed Web of Science ®Google Scholar
• Wang X, Li X, Ito A, Sogo Y, Ohno T Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site.
   Google Scholar
• Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557–24. doi:10.1038/nri3254.
   PubMed Web of Science ®Google Scholar
• Blander JM. Regulation of the cell biology of antigen cross-presentation. Annu Rev Immunol. 2018;36(1):717–53. doi:10.1146/annurev-immunol-041015-055523.
   PubMedGoogle Scholar
• Alloatti A, Kotsias F, Magalhaes JG, Amigorena S. Dendritic cell maturation and cross-presentation: timing matters! Immunol Rev. 2016;272(1):97–108. doi:10.1111/imr.12432.
   PubMed Web of Science ®Google Scholar
• Santos PM, Butterfield LH. Dendritic cell–based cancer vaccines. J Immunol. 2018;200(2):443–9. doi:10.4049/jimmunol.1701024.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. doi:10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar
• Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol. 2009;27(2):129–39. doi:10.1038/nbt0209-129.
   PubMed Web of Science ®Google Scholar
• Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014;106(11). doi:10.1093/jnci/dju268.
   PubMedGoogle Scholar
• Sutherland SIM, Ju X, Horvath LG, Clark GJ. Moving on from sipuleucel-T: new dendritic cell vaccine strategies for prostate cancer. Front Immunol. 2021;12:641307. doi:10.3389/fimmu.2021.641307.
   PubMed Web of Science ®Google Scholar
• Holl EK, McNamara MA, Healy P, Anand M, Concepcion RS, Breland CD, Dumbudze I, Tutrone R, Shore N, Armstrong AJ, et al. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis. 2019;22(4):588–92. doi:10.1038/s41391-019-0144-3.
   PubMed Web of Science ®Google Scholar
• Yang H, Zhou H, Huang Z, Tao K, Huang N, Peng Z, Feng W, et al. Induction of CML-specific immune response through cross-presentation triggered by CTP-mediated BCR-ABL-derived peptides. Cancer Lett. 2020;482:44–55. doi:10.1016/j.canlet.2020.04.010.
   PubMed Web of Science ®Google Scholar
• Marciscano AE, Anandasabapathy N. The role of dendritic cells in cancer and anti-tumor immunity. Semin Immunol. 2021;52:101481. doi:10.1016/j.smim.2021.101481.
   PubMed Web of Science ®Google Scholar
• Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, Casanova-Acebes M, Khudoynazarova M, Agudo J, Tung N, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44(4):924–38. doi:10.1016/j.immuni.2016.03.012.
   PubMed Web of Science ®Google Scholar
• Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, Kaisho T, Bogunovic D, Bhardwaj N, Krummel MF, et al. Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 2016;30(2):324–36. doi:10.1016/j.ccell.2016.06.003.
   PubMed Web of Science ®Google Scholar
• Lee W, Suresh M. Vaccine adjuvants to engage the cross-presentation pathway. Front Immunol. 2022;13:940047. doi:10.3389/fimmu.2022.940047.
   PubMed Web of Science ®Google Scholar
• Audsley KM, McDonnell AM, Waithman J. Cross-presenting XCR1(+) dendritic cells as targets for cancer immunotherapy. Cells. 2020;9(3):565. doi:10.3390/cells9030565.
   PubMed Web of Science ®Google Scholar
• Shae D, Baljon JJ, Wehbe M, Christov PP, Becker KW, Kumar A, Suryadevara N, Carson CS, Palmer CR, Knight FC, et al. Co-delivery of peptide neoantigens and stimulator of interferon genes agonists enhances response to cancer vaccines. ACS Nano. 2020;14(8):9904–16. doi:10.1021/acsnano.0c02765.
   PubMed Web of Science ®Google Scholar
• Liu W, Tang H, Li L, Wang X, Yu Z, Li J. Peptide-based therapeutic cancer vaccine: Current trends in clinical application. Cell Prolif. 2021;54(5):e13025. doi:10.1111/cpr.13025.
   PubMed Web of Science ®Google Scholar
• Kissick HT, Sanda MG, Dunn LK, Arredouani MS, van Hall T. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. PloS One. 2014;9(4):e93231. doi:10.1371/journal.pone.0093231.
   PubMed Web of Science ®Google Scholar
• Liu Y, Song Z, Zhou B, Fu X, Wu M, Butterfield LH. An in vitro study on the inhibition of hepatocellular carcinoma growth by AFP-specific CD8 + T/CD4 + T activated by lentivirally engineered and AFP pulsed DC. J Tongji Univ. 2011;32:18–23.
   Google Scholar
• Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2017;17(3):1326–35. doi:10.1021/acs.nanolett.6b03329.
   PubMed Web of Science ®Google Scholar
• Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144–50. doi:10.1038/s41586-023-06063-y.
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos CE, Eickhoff JC, Ferrari AC, Schweizer MT, Wargowski E, Olson BM, McNeel DG. Multicenter phase I trial of a DNA vaccine encoding the androgen receptor ligand-binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer. Clin Cancer Res. 2020;26(19):5162–71. doi:10.1158/1078-0432.CCR-20-0945.
   PubMed Web of Science ®Google Scholar
• Graván P, Aguilera-Garrido A, Marchal JA, Navarro-Marchal SA, Galisteo-González F. Lipid-core nanoparticles: classification, preparation methods, routes of administration and recent advances in cancer treatment. Adv Colloid Interface Sci. 2023;314:102871. doi:10.1016/j.cis.2023.102871.
   PubMed Web of Science ®Google Scholar
• Qiu Z, Huang H, Grenier JM, Perez OA, Smilowitz HM, Adler B, Khanna KM. Cytomegalovirus-based vaccine expressing a modified tumor antigen induces potent tumor-specific CD8(+) T-cell response and protects mice from melanoma. Cancer Immunol Res. 2015;3(5):536–46. doi:10.1158/2326-6066.CIR-14-0044.
   PubMed Web of Science ®Google Scholar
• Tršan T, Vuković K, Filipović P, Brizić AL, Lemmermann NAW, Schober K, Busch DH, Britt WJ, Messerle M, Krmpotić A, et al. Cytomegalovirus vector expressing RAE-1γ induces enhanced anti-tumor capacity of murine CD8 + T cells. Eur J Immunol. 2017;47(8):1354–67. doi:10.1002/eji.201746964.
   PubMed Web of Science ®Google Scholar
• D’Alise AM, Brasu N, De Intinis C, Leoni G, Russo V, Langone F, Baev D, Micarelli E, Petiti L, Picelli S, et al. Adenoviral-based vaccine promotes neoantigen-specific CD8 + T cell stemness and tumor rejection. Sci Transl Med. 2022;14(657):eabo7604. doi:10.1126/scitranslmed.abo7604.
   PubMed Web of Science ®Google Scholar
• Svensson-Arvelund J, Cuadrado-Castano S, Pantsulaia G, Kim K, Aleynick M, Hammerich L, Upadhyay R, Yellin M, Marsh H, Oreper D, et al. Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity. Nat Commun. 2022;13(1):7149. doi:10.1038/s41467-022-34791-8.
   PubMed Web of Science ®Google Scholar
• Baharom F, Ramirez-Valdez RA, Tobin KKS, Yamane H, Dutertre CA, Khalilnezhad A, Reynoso GV, Coble VL, Lynn GM, Mulè MP, et al. Intravenous nanoparticle vaccination generates stem-like TCF1(+) neoantigen-specific CD8(+) T cells. Nat Immunol. 2021;22(1):41–52. doi:10.1038/s41590-020-00810-3.
   PubMed Web of Science ®Google Scholar
• Park KS, Nam J, Son S, Moon JJ. Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8(+) T cells. Biomaterials. 2021;274:120844. doi:10.1016/j.biomaterials.2021.120844.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhang S, Han N, Jiang J, Xu Y, Ma D, Lu L, Guo X, Qiu M, Huang Q, et al. A neoantigen-based peptide vaccine for patients with advanced pancreatic cancer refractory to standard treatment. Front Immunol. 2021;12:691605. doi:10.3389/fimmu.2021.691605.
   PubMed Web of Science ®Google Scholar
• Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, Poran A, Sheen JH, Kohler V, Esaulova E, et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell. 2022;40(9):1010–26.e11. doi:10.1016/j.ccell.2022.08.003.
   PubMed Web of Science ®Google Scholar
• Adotevi O, Dosset M, Galaine J, Beziaud L, Godet Y, Borg C. Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. Hum Vaccin Immunother. 2013;9(5):1073–7. doi:10.4161/hv.23587.
   PubMed Web of Science ®Google Scholar
• Kumai T, Lee S, Cho HI, Sultan H, Kobayashi H, Harabuchi Y, Celis E. Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses. Cancer Immunol Res. 2017;5(1):72–83. doi:10.1158/2326-6066.CIR-16-0194.
   PubMed Web of Science ®Google Scholar
• Chen J, Ye Z, Huang C, Qiu M, Song D, Li Y, Xu Q. Lipid nanoparticle-mediated lymph node–targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc Natl Acad Sci USA. 2022;119(34):e2207841119. doi:10.1073/pnas.2207841119.
   PubMed Web of Science ®Google Scholar
• Amaya L, Grigoryan L, Li Z, Lee A, Wender PA, Pulendran B, Chang HY. Circular RNA vaccine induces potent T cell responses. Proc Natl Acad Sci USA. 2023;120(20):e2302191120. doi:10.1073/pnas.2302191120.
   PubMed Web of Science ®Google Scholar
• Daiko H, Marafioti T, Fujiwara T, Shirakawa Y, Nakatsura T, Kato K, Puccio I, Hikichi T, Yoshimura S, Nakagawa T, et al. Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients. Cancer Immunol Immunother. 2020;69(11):2247–57. doi:10.1007/s00262-020-02619-3.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Ciuleanu T, Domine M, Szczesna A, Bover I, Cobo M, Kentepozidis N, Zarogoulidis K, Kalofonos C, Kazarnowisz A, et al. Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial. Br J Cancer. 2020;122(10):1461–6. doi:10.1038/s41416-020-0785-y.
   PubMed Web of Science ®Google Scholar
• Hirokazu O, Taylor JW, Takahide N, David G, Watchmaker PB, Kaori O, Saijo A, Tedesco MR, Shai A, Wong CM, et al. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T-cell response in low-grade gliomas. J Clin Invest. 2022;132(3). doi:10.1172/jci151239.
   Web of Science ®Google Scholar
• Frank MJ, Khodadoust MS, Czerwinski DK, Haabeth OA, Chu MP, Miklos DB, Advani RH, Alizadeh AA, Gupta NK, Maeda LS, et al. Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: a phase I/II trial. J Exp Med. 2020;217(9). doi:10.1084/jem.20191712.
   PubMed Web of Science ®Google Scholar
• Crosby EJ, Gwin W, Blackwell K, Marcom PK, Chang S, Maecker HT, Broadwater G, Hyslop T, Kim S, Rogatko A, et al. Vaccine-induced memory CD8(+) T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study. Clin Cancer Res. 2019;25(9):2725–36. doi:10.1158/1078-0432.CCR-18-3102.
   PubMed Web of Science ®Google Scholar
• Mousset CM, Hobo W, Woestenenk R, Preijers F, Dolstra H, van der Waart AB. Comprehensive phenotyping of T cells using flow cytometry. Cytometry A. 2019;95(6):647–54. doi:10.1002/cyto.a.23724.
   PubMedGoogle Scholar
• Saravia J, Chapman NM, Chi H. Helper T cell differentiation. Cell Mol Immunol. 2019;16(7):634–43. doi:10.1038/s41423-019-0220-6.
   PubMed Web of Science ®Google Scholar
• Cenerenti M, Saillard M, Romero P, Jandus C. The era of cytotoxic CD4 T cells. Front Immunol. 2022;13:867189. doi:10.3389/fimmu.2022.867189.
   PubMedGoogle Scholar
• Porakishvili N, Roschupkina T, Kalber T, Jewell AP, Patterson K, Yong K, Lydyard PM. Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL). Clin Exp Immunol. 2001;126(1):29–36. doi:10.1046/j.1365-2249.2001.01639.x.
   PubMed Web of Science ®Google Scholar
• Fu J, Wang F. Research progress of CD4+ killing T cells in viral infection and tumor diseases. Chin J Cell Mol Immunol. 2012;28:102–4.
   Google Scholar
• Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207(3):637–50. doi:10.1084/jem.20091918.
   PubMed Web of Science ®Google Scholar
• Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S, Yuan JD, Wolchok JD, et al. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res. 2013;1(4):235–44. doi:10.1158/2326-6066.CIR-13-0068.
   PubMed Web of Science ®Google Scholar
• Zhou L, Wang H, Fu J, Chen Y, Li Y, Chen L, Sa LV, Wang FS. Study on the correlation between CD4+ cytotoxic T and course of primary hepatocellular carcinoma. Med J Chin People’s Liberation Army. 2013;38:137–40.
   Google Scholar
• Tang XX, Shimada H, Ikegaki N. Clinical relevance of CD4 cytotoxic T cells in high-risk neuroblastoma. Front Immunol. 2021;12:650427. doi:10.3389/fimmu.2021.650427.
   PubMed Web of Science ®Google Scholar
• Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, Nainys J, Wu K, Kiseliovas V, Setty M, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174(5):1293–308 e36. doi:10.1016/j.cell.2018.05.060.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yang D, Yang Q, Lv X, Huang W, Zhou Z, Wang Y, Zhang Z, Yuan T, Ding X, et al. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat Commun. 2020;11(1):6322. doi:10.1038/s41467-020-20059-6.
   PubMed Web of Science ®Google Scholar
• Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008;358(25):2698–703. doi:10.1056/NEJMoa0800251.
   PubMed Web of Science ®Google Scholar
• Anastasopoulou EA, Voutsas IF, Papamichail M, Baxevanis CN, Perez SA. MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4 + T-cells. Oncoimmunology. 2016;5(7):e1178439. doi:10.1080/2162402X.2016.1178439.
   PubMed Web of Science ®Google Scholar
• Vergati M, Schlom J, Tsang KY. The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring. J Biomed Biotechnol. 2011;2011:182413. doi:10.1155/2011/182413.
   PubMedGoogle Scholar
• Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101(5):455–8. doi:10.1016/S0092-8674(00)80856-9.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490–500. doi:10.1038/nri2785.
   PubMed Web of Science ®Google Scholar
• Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother. 2004;53(10):844–54. doi:10.1007/s00262-004-0540-x.
   PubMed Web of Science ®Google Scholar
• Wiedermann U, Garner-Spitzer E, Chao Y, Maglakelidze M, Bulat I, Dechaphunkul A, Arpornwirat W, Charoentum C, Yen C-J, Yau TC, et al. Clinical and immunologic responses to a B-cell epitope vaccine in patients with HER2/neu-overexpressing advanced gastric cancer—results from phase Ib trial IMU.ACS.001. Clin Cancer Res. 2021;27(13):3649–60. doi:10.1158/1078-0432.CCR-20-3742.
   PubMed Web of Science ®Google Scholar
• Wada M, Tsuchikawa T, Kyogoku N, Abiko T, Miyauchi K, Takeuchi S, Kuwatani T, Shichinohe T, Miyahara Y, Kageyama S, et al. Clinical implications of CD4(+)CD25(+)Foxp3(+)Regulatory T cell frequencies after CHP-MAGE-A4 cancer vaccination. Anticancer Res. 2018;38:1435–44.
   PubMed Web of Science ®Google Scholar
• Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108(3):804–11. doi:10.1182/blood-2006-02-002774.
   PubMed Web of Science ®Google Scholar
• Mousavi-Niri N, Naseroleslami M, Hadjati J. Anti-regulatory T cell vaccines in immunotherapy: focusing on FoxP3 as target. Hum Vaccin Immunother. 2019;15(3):620–4. doi:10.1080/21645515.2018.1545625.
   PubMed Web of Science ®Google Scholar
• Miguel A, Sendra L, Noé V, Ciudad CJ, Dasí F, Hervas D, Herrero MJ, Aliño S. Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma. Onco Targets Ther. 2017;10:503–14. doi:10.2147/OTT.S104393.
   PubMed Web of Science ®Google Scholar
• Namdar A, Mirzaei R, Memarnejadian A, Boghosian R, Samadi M, Mirzaei HR, Farajifard H, Zavar M, Azadmanesh K, Elahi S, et al. Prophylactic DNA vaccine targeting Foxp3(+) regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model. Cancer Immunol Immunother. 2018;67(3):367–79. doi:10.1007/s00262-017-2088-6.
   PubMed Web of Science ®Google Scholar
• Mousavi Niri N, Memarnejadian A, Hadjati J, Aghasadeghi MR, Shokri M, Pilehvar-Soltanahmadi Y, Akbarzadeh A, Zarghami N. Construction and production of Foxp3-Fc (IgG) DNA vaccine/fusion protein. Avicenna J Med Biotechnol. 2016;8:57–64.
   PubMedGoogle Scholar
• Mousavi Niri N, Memarnejadian A, Pilehvar-Soltanahmadi Y, Agha Sadeghi M, Mahdavi M, Kheshtchin N, Arab S, Namdar A, Jadidi F, Zarghami N, et al. Improved anti-Treg vaccination targeting Foxp3 efficiently decreases regulatory T cells in mice. J Immunother (1991). 2016;39(7):269–75. doi:10.1097/CJI.0000000000000133.
   Web of Science ®Google Scholar
• Mattarollo SR, Steegh K, Li M, Duret H, Foong Ngiow S, Smyth MJ. Transient Foxp3+ regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. Immunol Cell Biol. 2013;91(1):105–14. doi:10.1038/icb.2012.58.
   PubMed Web of Science ®Google Scholar
• Yan J, Tingey C, Lyde R, Gorham TC, Choo DK, Muthumani A, Myles D, Weiner LP, Kraynyak KA, Reuschel EL, et al. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model. Cancer Gene Ther. 2014;21(12):507–17. doi:10.1038/cgt.2014.56.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao Q, Zhao B, Zheng Y, Zhuang Q, Liao N, Wang P, Cai Z, Zhang D, Zeng Y, et al. Remodeling tumor-associated neutrophils to enhance dendritic cell-based HCC neoantigen nano-vaccine efficiency. Adv Sci. 2022;9(11):e2105631. doi:10.1002/advs.202105631.
   Web of Science ®Google Scholar
• Gottschalk S, Yu F, Ji M, Kakarla S, Song XT, Haass NK. A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading. PloS One. 2013;8(12):e82658. doi:10.1371/journal.pone.0082658.
   PubMed Web of Science ®Google Scholar
• Chen M, Xiang R, Wen Y, Xu G, Wang C, Luo S, Yin T, Wei X, Shao B, Liu N, et al. A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts. Sci Rep. 2015;5(1):14421. doi:10.1038/srep14421.
   PubMed Web of Science ®Google Scholar
• Qian L, Tang Z, Yin S, Mo F, Yang X, Hou X, Liu A, Lu X. Fusion of dendritic cells and cancer-associated fibroblasts for activation of anti-tumor cytotoxic T lymphocytes. J Biomed Nanotechnol. 2018;14(10):1826–35. doi:10.1166/jbn.2018.2616.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang L, Wen W, Hao J, Zeng P, Qian X, Zhang Y, Yin Y. Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice. PloS One. 2012;7(10):e47219. doi:10.1371/journal.pone.0047219.
   PubMed Web of Science ®Google Scholar
• Yang Y, Che Y, Zhao Y, Wang X. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo. Int Immunopharmacol. 2019;69:279–88. doi:10.1016/j.intimp.2019.01.024.
   PubMed Web of Science ®Google Scholar
• Schuler JP, Malgorzata H, Carmen V, Albert D, Sumita T, Yu L, Argiris A, Gooding W, Butterfield LH, Whiteside TL, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. 2014;20(9):2433–44. doi:10.1158/1078-0432.CCR-13-2617.
   PubMed Web of Science ®Google Scholar
• Holleb AI, Folkman J. Tumor angiogenesis. CA Cancer J Clin. 1972;22:226–9.
   PubMedGoogle Scholar
• Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med. 1975;82(1):96–100. doi:10.7326/0003-4819-82-1-96.
   PubMed Web of Science ®Google Scholar
• 侯建梅, 田聆, 魏于全. 抗肿瘤血管生成免疫治疗的研究进展. 中国科学(C辑:生命科学). 2004;34(3):203–9.
   Google Scholar
• Neek M, Kim TI, Wang SW. Protein-based nanoparticles in cancer vaccine development. Nanomedicine. 2019;15(1):164–74. doi:10.1016/j.nano.2018.09.004.
   PubMed Web of Science ®Google Scholar
• Shahnazari M, Samadi P, Pourjafar M, Jalali A. Therapeutic vaccines for colorectal cancer: the progress and future prospect. Int Immunopharmacol. 2020;88:106944. doi:10.1016/j.intimp.2020.106944.
   PubMed Web of Science ®Google Scholar
• Kim CG, Sang YB, Lee JH, Chon HJ. Combining cancer vaccines with immunotherapy: establishing a new immunological approach. Int J Mol Sci. 2021;22(15):22. doi:10.3390/ijms22158035.
   Web of Science ®Google Scholar
• Wagner S, Mullins CS, Linnebacher M. Colorectal cancer vaccines: tumor-associated antigensvsneoantigens. World J Gastroentero. 2018;24(48):5418–32. doi:10.3748/wjg.v24.i48.5418.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a National cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323–37. doi:10.1158/1078-0432.CCR-09-0737.
   PubMed Web of Science ®Google Scholar
• Lladser A, Párraga M, Quevedo L, Carmen Molina M, Silva S, Ferreira A, Billetta R, Quest AF. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice. Immunobiology. 2006;211(1–2):11–27. doi:10.1016/j.imbio.2005.08.002.
   PubMed Web of Science ®Google Scholar
• Lladser A, Ljungberg K, Tufvesson H, Tazzari M, Roos A-K, Quest AFG, Kiessling R. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother. 2009;59(1):81–92. doi:10.1007/s00262-009-0725-4.
   PubMed Web of Science ®Google Scholar
• Chen R, Wang S, Yao Y, Zhou YUN, Zhang C, Fang JIE, Zhang D, Zhang L, Pan J. Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide. Oncol Rep. 2015;33(5):2269–76. doi:10.3892/or.2015.3820.
   PubMed Web of Science ®Google Scholar
• Yin X, Wang W, Zhu X, Wang Y, Wu S, Wang Z, Wang L, Du Z, Gao J, Yu J, et al. Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis. Biochem Bioph Res Co. 2015;465(2):239–44. doi:10.1016/j.bbrc.2015.08.003.
   PubMed Web of Science ®Google Scholar
• Ruan J, Duan Y, Li F, Wang Z. Enhanced synergistic anti-Lewis lung carcinoma effect of a DNA vaccine harboring a MUC1-VEGFR2 fusion gene used with GM-CSF as an adjuvant. Clin Exp Pharmacol Physiol. 2017;44(1):71–8. doi:10.1111/1440-1681.12654.
   PubMed Web of Science ®Google Scholar
• Gao J, Fan L, Ma W, Xiao H. Synergistic antitumor effect of a human papillomavirus DNA vaccine harboring E6E7 fusion gene and vascular endothelial growth factor receptor 2 gene. Microbiol Immunol. 2016;60(9):626–33. doi:10.1111/1348-0421.12408.
   PubMed Web of Science ®Google Scholar
• Zahedipour F, Zamani P, Mashreghi M, Astaneh M, Sankian M, Amiri A, Jamialahmadi K, Jaafari MR. Nanoliposomal VEGF-R2 peptide vaccine acts as an effective therapeutic vaccine in a murine B16F10 model of melanoma. Cancer Nanotechnol. 2023;14(1):14. doi:10.1186/s12645-023-00213-7.
   Web of Science ®Google Scholar
• Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P, Hicklin DJ, et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med. 2002;195(12):1575–84. doi:10.1084/jem.20020072.
   PubMed Web of Science ®Google Scholar
• Pan J, Heiser A, Marget M, Steinmann J, Kabelitz D. Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination. Gene Ther. 2005;12(9):742–50. doi:10.1038/sj.gt.3302470.
   PubMed Web of Science ®Google Scholar
• Yan HX, Cheng P, Wei HY, Shen GB, Fu LX, Ni J, Wu Y, Wei Y-Q. Active immunotherapy for mouse breast cancer with irradiated whole-cell vaccine expressing VEGFR2. Oncol Rep. 2013;29(4):1510–16. doi:10.3892/or.2013.2282.
   PubMed Web of Science ®Google Scholar
• Zuo SG, Chen Y, Wu ZP, Liu X, Liu C, Zhou YC, Wu CL, Jin CG, Gu YL, Li J, et al. Orally administered DNA vaccine delivery by attenuated Salmonella typhimurium targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis. Biol Pharm Bull. 2010;33(2):174–82. doi:10.1248/bpb.33.174.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang Y, Wu Y, Ding ZY, Luo XM, Zhong WN, Liu J, Xia X-Y, Deng G-H, Deng Y-T, et al. Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity. J Cancer Res Clin Oncol. 2014;140(5):701–12. doi:10.1007/s00432-014-1606-6.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang J, Wu Y, Ding ZY, Luo XM, Liu J, Zhong W-N, Deng G-H, Xia X-Y, Deng Y-T, et al. Mannan-modified adenovirus targeting TERT and VEGFR-2: a universal tumour vaccine. Sci Rep. 2015;5(1):11275. doi:10.1038/srep11275.
   PubMedGoogle Scholar
• Zhang H, Jia E, Xia W, Lv T, Lu C, Xu Z, Zhu W. Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. Vaccine. 2019;37(15):2090–8. doi:10.1016/j.vaccine.2019.02.055.
   PubMed Web of Science ®Google Scholar
• Kan B, Yang L, Wen YJ, Yang JR, Niu T, Li J, Deng H-X, Wei W, Chen L-G, Zhang Q, et al. Irradiated VEGF164-modified tumor cell vaccine protected mice from the parental tumor challenge. Anticancer Drugs. 2017;28(2):197–205. doi:10.1097/CAD.0000000000000447.
   PubMed Web of Science ®Google Scholar
• Zhou J, Xi Y, Mu X, Zhao R, Chen H, Zhang L, Wu Y, Li Q. Antitumor immunity induced by VE-cadherin modified DC vaccine. Oncotarget. 2017;8(40):67369–79. doi:10.18632/oncotarget.18654.
   PubMedGoogle Scholar
• Chen Y, Liu X, Jin CG, Zhou YC, Navab R, Jakobsen KR, Chen XQ, Li J, Li TT, Luo L, et al. An orally administered DNA vaccine targeting vascular endothelial growth factor receptor-3 inhibits lung carcinoma growth. Tumor Biol. 2015;37(2):2395–404. doi:10.1007/s13277-015-4061-3.
   PubMedGoogle Scholar
• Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, Nakamura Y, Yamaue H. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010;101(2):433–9. doi:10.1111/j.1349-7006.2009.01416.x.
   PubMed Web of Science ®Google Scholar
• Okamoto I, Arao T, Miyazaki M, Satoh T, Okamoto K, Tsunoda T, Nishio K, Nakagawa K. Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. Cancer Sci. 2012;103(12):2135–8. doi:10.1111/cas.12014.
   PubMed Web of Science ®Google Scholar
• Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC study. Cancer Sci. 2015;106(7):883–90. doi:10.1111/cas.12674.
   PubMed Web of Science ®Google Scholar
• Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Osawa R, et al. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012;41(4):1297–304. doi:10.3892/ijo.2012.1573.
   PubMed Web of Science ®Google Scholar
• Matsushita N, Aruga A, Inoue Y, Kotera Y, Takeda K, Yamamoto M. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer. Oncol Rep. 2013;29(3):951–9. doi:10.3892/or.2013.2231.
   PubMed Web of Science ®Google Scholar
• Okuyama R, Aruga A, Hatori T, Takeda K, Yamamoto M. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Oncoimmunology. 2013;2(11):e27010. doi:10.4161/onci.27010.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Fukuhara M, Yamaura T, Mutoh S, Okabe N, Yaginuma H, Hasegawa T, Yonechi A, Osugi J, Hoshino M, et al. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J Transl Med. 2013;11(1):97. doi:10.1186/1479-5876-11-97.
   PubMed Web of Science ®Google Scholar
• Hazama S, Nakamura Y, Takenouchi H, Suzuki N, Tsunedomi R, Inoue Y, Tokuhisa Y, Iizuka N, Yoshino S, Takeda K, et al. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J Transl Med. 2014;12(1):63. doi:10.1186/1479-5876-12-63.
   PubMedGoogle Scholar
• Okuno K, Sugiura F, Inoue K, Sukegawa Y. Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for patients with metastatic colorectal cancer. Anticancer Res. 2014;34:3045–52.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Ikeda Y, Kunugi Y, Kurosaki A, Imai Y, Kohyama S, Nagao S, Kozawa E, Yoshida K, Tsunoda T, et al. Phase I study of multiple epitope peptide vaccination in patients with recurrent or persistent cervical cancer. J Immunother (1991). 2018;41(4):201–7. doi:10.1097/CJI.0000000000000214.
   PubMed Web of Science ®Google Scholar
• Shibao S, Ueda R, Saito K, Kikuchi R, Nagashima H, Kojima A, Kagami H, Pareira ES, Sasaki H, Noji S, et al. A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma. Oncotarget. 2018;9(30):21569–79. doi:10.18632/oncotarget.25131.
   PubMedGoogle Scholar
• Kikuchi R, Ueda R, Saito K, Shibao S, Nagashima H, Tamura R, Morimoto Y, Sasaki H, Noji S, Kawakami Y, et al. A Pilot study of vaccine therapy with multiple glioma oncoantigen/glioma angiogenesis-associated antigen peptides for patients with recurrent/progressive high-grade glioma. J Clin Med. 2019;8(2):263. doi:10.3390/jcm8020263.
   PubMed Web of Science ®Google Scholar
• Tamura R, Fujioka M, Morimoto Y, Ohara K, Kosugi K, Oishi Y, Sato M, Ueda R, Fujiwara H, Hikichi T, et al. A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2. Nat Commun. 2019;10(1):5758. doi:10.1038/s41467-019-13640-1.
   PubMedGoogle Scholar
• Tamura R, Morimoto Y, Kosugi K, Sato M, Oishi Y, Ueda R, Kikuchi R, Nagashima H, Hikichi T, Noji S, et al. Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series. BMC Cancer. 2020;20(1):196. doi:10.1186/s12885-020-6589-x.
   PubMed Web of Science ®Google Scholar
• Miyazawa M, Katsuda M, Maguchi H, Katanuma A, Ishii H, Ozaka M, Yamao K, Imaoka H, Kawai M, Hirono S, et al. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Int J Cancer. 2017;140(4):973–82. doi:10.1002/ijc.30510.
   PubMed Web of Science ®Google Scholar
• Suzuki N, Hazama S, Iguchi H, Uesugi K, Tanaka H, Hirakawa K, Aruga A, Hatori T, Ishizaki H, Umeda Y, et al. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci. 2017;108(1):73–80. doi:10.1111/cas.13113.
   PubMed Web of Science ®Google Scholar
• Hazama S, Nakamura Y, Tanaka H, Hirakawa K, Tahara K, Shimizu R, Ozasa H, Etoh R, Sugiura F, Okuno K, et al. A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med. 2014;12(1):108. doi:10.1186/1479-5876-12-108.
   PubMedGoogle Scholar
• Kanekiyo S, Hazama S, Takenouchi H, Nakajima M, Shindo Y, Matsui H, Tokumitsu Y, Tomochika S, Tsunedomi R, Tokuhisa Y, et al. IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides. Oncol Rep. 2018;39:2385–92. doi:10.3892/or.2018.6288.
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Kagabu M, Shoji T, Nitta Y, Sugiyama T, Sato J, Nakamura Y. Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]. Oncoimmunology. 2020;9(1):1838189. doi:10.1080/2162402X.2020.1838189.
   PubMed Web of Science ®Google Scholar
• Tamura R, Morimoto Y, Sato M, Hikichi T, Yoshida K, Toda M. A pilot study of the adverse events caused by the combined use of bevacizumab and vascular endothelial growth factor receptor-targeted vaccination for patients with a malignant glioma. Vaccines (Basel). 2020;8(3):498. doi:10.3390/vaccines8030498.
   PubMed Web of Science ®Google Scholar
• Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, Yamamoto M, Yagihashi A, Ohmura T, Yamaguchi K, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med. 2004;2(1):19. doi:10.1186/1479-5876-2-19.
   PubMedGoogle Scholar
• Tsuruma T, Iwayama Y, Ohmura T, Katsuramaki T, Hata F, Furuhata T, Yamaguchi K, Kimura Y, Torigoe T, Toyota N, et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med. 2008;6(1):24. doi:10.1186/1479-5876-6-24.
   PubMed Web of Science ®Google Scholar
• Kameshima H, Tsuruma T, Torigoe T, Takahashi A, Hirohashi Y, Tamura Y, Tsukahara T, Ichimiya S, Kanaseki T, Iwayama Y, et al. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci. 2011;102(6):1181–7. doi:10.1111/j.1349-7006.2011.01918.x.
   PubMed Web of Science ®Google Scholar
• Kameshima H, Tsuruma T, Kutomi G, Shima H, Iwayama Y, Kimura Y, Imamura M, Torigoe T, Takahashi A, Hirohashi Y, et al. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci. 2013;104(1):124–9. doi:10.1111/cas.12046.
   PubMed Web of Science ®Google Scholar
• Shima H, Tsurita G, Wada S, Hirohashi Y, Yasui H, Hayashi H, Miyakoshi T, Watanabe K, Murai A, Asanuma H, et al. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma. Cancer Sci. 2019;110(8):2378–85. doi:10.1111/cas.14106.
   PubMed Web of Science ®Google Scholar
• Niethammer AG, Lubenau H, Mikus G, Knebel P, Hohmann N, Leowardi C, Beckhove P, Akhisaroglu M, Ge Y, Springer M, et al. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. BMC Cancer. 2012;12(1):361. doi:10.1186/1471-2407-12-361.
   PubMedGoogle Scholar
• Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, et al. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: a randomized, placebo-controlled, phase 1 trial. Oncoimmunology. 2015;4(4):e1001217. doi:10.1080/2162402X.2014.1001217.
   PubMed Web of Science ®Google Scholar
• Yang W, Zhang W, Wang X, Tan L, Li H, Wu J, Wu Q, Sun W, Chen J, Yin Y, et al. HCA587 protein vaccine induces specific antitumor immunity mediated by CD4(+) T-cells expressing granzyme B in a mouse model of melanoma. Anticancer Agents Med Chem. 2021;21(6):738–46. doi:10.2174/1871520620666200728131951.
   PubMed Web of Science ®Google Scholar
• Lokhov PG, Mkrtichyan M, Mamikonyan G, EE B. SANTAVAC(TM): summary of research and development. Vaccines (Basel). 2019;7(4):186. doi:10.3390/vaccines7040186.
   PubMed Web of Science ®Google Scholar
• Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O, Baxter AE, Herati RS, Oldridge DA, Gouma S, et al. Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity. 2021;54(9):2133–2142 e3. doi:10.1016/j.immuni.2021.08.001.
   Google Scholar
• Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, Poran A, Sheen JH, Kohler V, Esaulova E, et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell. 2022;40(9):1010–1026.e11. doi:10.1016/j.ccell.2022.08.003.
   Google Scholar